Coming off a year that saw a record number of new drug approvals, significant scientific breakthroughs and a year-end tax reform package that both significantly lowers corporate taxes and provides the long-awaited tax repatriation holiday, it’s not surprising that biotech investors, executives and advisers were in a good mood as they gathered in San Francisco this year for the J.P. Morgan Healthcare Conference. The skies may have been cloudy, but spirits were high, fueled by… Continue Reading